Newer therapies - DiabetesontheNet

The SGLT2 inhibitors – where are we now?

Letter from Novo Nordisk Ltd

Conference report: 12th National Conference of the PCDS

Could non-physician clinical care have a role in the UK?

Semaglutide and SUSTAIN-6: Another step towards the holy grail of type 2 diabetes management?

Utility of antidiabetes medications in chronic kidney disease: A review

Putting type 2 diabetes into remission: Moving towards non-surgical interventions in the future

Real-world experience of SGLT2 inhibitors: A useful addition to the arsenal of antidiabetes medication. An Irish perspective

Glucagon-like peptide-1 receptor agonists: A better option for treating and preventing steatohepatitis?

EMPA-REG Renal: Are we there yet?

Keeping abreast of the latest diabetes research: Glycaemic control, hypoglycaemia, combination therapy and inpatient care

A new age in management of type 2 diabetes treatment

Experience of and predictors of response to dapagliflozin in a real-life cohort of people with type 2 diabetes

Evaluation of a combination of SGLT2 inhibitor and GLP-1 receptor agonist treatment in type 2 diabetes

Keeping abreast of the latest diabetes research: Impact of diabetes, hypoglycaemia awareness and GLP-1 analogues

Recent PCDS activities

Diabetes and bone health

Very-low-energy diets: A useful tool in type 2 diabetes management?